{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:56:30Z","timestamp":1790722590450,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The ARAMIS study was funded by Bayer AG and Orion Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In ARAMIS, darolutamide statistically significantly prolonged metastasis-free survival by 2 years and reduced the risk of death by 31% in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We report post hoc analyses of ARAMIS evaluating patterns of disease progression overall and by prostate-specific antigen (PSA) response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients were randomized 2:1 to darolutamide (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009955) or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009554), with androgen-deprivation therapy (ADT). Progression included metastases on conventional imaging, PSA progression based on Prostate Cancer Working Group 2 criteria or any rise in PSA, and pain progression. Radiological progression was compared between patients who reached undetectable PSA\u2009&lt;\u20090.2\u2009ng\/ml at any time and those who did not.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Metastatic progression occurred in 14% of patients receiving darolutamide versus 29% of patients receiving placebo, with a consistent pattern mostly isolated to bone (46%; 39%) or lymph nodes (32%; 40%). At 12 months, fewer patients receiving darolutamide versus placebo had PSA progression alone (7.8% vs. 35.9%) or both PSA and radiological progression (5.4% vs. 21.4%). Radiological progression without PSA progression occurred in 35% of metastatic events in the darolutamide group and 23% of metastatic events in the placebo group. Darolutamide led to deep PSA response (&lt;\u20090.2\u2009ng\/ml) versus placebo (25.1% vs. 0.5%), and patients receiving darolutamide who reached PSA\u2009&lt;\u20090.2\u2009ng\/ml experienced less radiological progression than those who did not (24 months: 8.7% vs. 33%; 36 months: 8.7% vs. 50%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Darolutamide plus ADT reduced the risk of metastatic progression and improved overall survival versus placebo plus ADT without changing patterns of disease progression through Month 24. Metastasis occurred without PSA progression in approximately 30% of metastatic events overall. Undetectable PSA with darolutamide was associated with reduced radiological progression that was maintained over time. These results highlight the importance of both imaging and PSA monitoring to identify disease progression in patients with nmCRPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-026-01076-w","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:34:57Z","timestamp":1770892497000},"page":"806-812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-4587","authenticated-orcid":false,"given":"Alicia K.","family":"Morgans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J. D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":false,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-1754","authenticated-orcid":false,"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Adorjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedeh","family":"Ghadessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"1076_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s40261-022-01178-y","volume":"42","author":"A Figueiredo","year":"2022","unstructured":"Figueiredo A, Costa L, Mauricio MJ, Figueira L, Ramos R, Martins-da-Silva C. Nonmetastatic castration-resistant prostate cancer: current challenges and trends. Clin Drug Investig. 2022;42:631\u201342.","journal-title":"Clin Drug Investig"},{"key":"1076_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2016.06.011","volume":"96","author":"DM Moreira","year":"2016","unstructured":"Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, et al. Predictors of time to metastasis in castration-resistant prostate cancer. Urology. 2016;96:171\u20136.","journal-title":"Urology"},{"key":"1076_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/pcan.2015.25","volume":"18","author":"DM Moreira","year":"2015","unstructured":"Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, et al. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:333\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1076_CR4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/cncr.25762","volume":"117","author":"MR Smith","year":"2011","unstructured":"Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011;117:2077\u201385.","journal-title":"Cancer"},{"key":"1076_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.urology.2013.10.026","volume":"83","author":"ED Crawford","year":"2014","unstructured":"Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, et al. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014;83:664\u20139.","journal-title":"Urology"},{"key":"1076_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209:1082\u201390.","journal-title":"J Urol"},{"key":"1076_CR7","doi-asserted-by":"crossref","unstructured":"Mottet N, Cornford P, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86:148\u201363.","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"1076_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/pcan.2016.71","volume":"20","author":"AH Bryce","year":"2017","unstructured":"Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017;20:221\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1076_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.eururo.2020.08.025","volume":"78","author":"F Saad","year":"2020","unstructured":"Saad F, Sternberg CN, Efstathiou E, Fizazi K, Modelska K, Lin X, et al. Prostate-specific antigen progression in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer: any rise in prostate-specific antigen may require closer monitoring. Eur Urol. 2020;78:847\u201353.","journal-title":"Eur Urol"},{"key":"1076_CR10","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.1200\/JCO.2022.40.16_suppl.5072","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Mottet N, Iguchi T, Szmulewitz RZ, Holzbeierlein J, Villers A, et al. Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of ARCHES. J Clin Oncol. 2022;40:5072.","journal-title":"J Clin Oncol"},{"key":"1076_CR11","doi-asserted-by":"crossref","unstructured":"Fukuokaya W, Yanagisawa T, Mori K, Urabe F, Rajwa P, Briganti A et al. Radiographic progression without corresponding prostate-specific antigen progression in patients with metastatic castration-sensitive prostate cancer receiving apalutamide: secondary analysis of the TITAN trial. Eur Urol Oncol 2024;8:263\u20139.","DOI":"10.1016\/j.euo.2024.04.009"},{"key":"1076_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235\u201346.","journal-title":"N Engl J Med"},{"key":"1076_CR13","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383:1040\u20139.","journal-title":"N Engl J Med"},{"key":"1076_CR14","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148\u201359.","journal-title":"J Clin Oncol"},{"key":"1076_CR15","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1076_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2013.07.001","volume":"40","author":"A Briganti","year":"2014","unstructured":"Briganti A, Suardi N, Gallina A, Abdollah F, Novara G, Ficarra V, et al. Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev. 2014;40:3\u201311.","journal-title":"Cancer Treat Rev"},{"key":"1076_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/JCO.2024.42.4_suppl.151","volume":"42","author":"ID Davis","year":"2024","unstructured":"Davis ID, Martin AJ, Zielinski RR, Thomson A, Tan T-H, Sandhu S, et al. Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): a retrospective analysis from the ENZAMET trial (ANZUP 1304). J Clin Oncol. 2024;42:151.","journal-title":"J Clin Oncol"},{"key":"1076_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/cncr.22372","volume":"109","author":"D Leibovici","year":"2007","unstructured":"Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, et al. Prostate cancer progression in the presence of an undetectable or low serum prostate-specific antigen level. Cancer. 2007;109:198\u2013204.","journal-title":"Cancer"},{"key":"1076_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/bco2.158","volume":"3","author":"S Malone","year":"2022","unstructured":"Malone S, Wallis CJD, Lee-Ying R, Basappa NS, Cagiannos I, Hamilton RJ, et al. Patterns of care for non-metastatic castration-resistant prostate cancer: a population-based study. BJUI Compass. 2022;3:383\u201391.","journal-title":"BJUI Compass"},{"key":"1076_CR20","doi-asserted-by":"crossref","unstructured":"Lapini A, Caffo O, Pappagallo G, Iacovelli R, D\u2019Angelillo RM, Vavassori V et al. Monitoring patients with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer: a multidisciplinary consensus document. Cancers 2019;11:1908.","DOI":"10.3390\/cancers11121908"},{"key":"1076_CR21","first-page":"735","volume":"71","author":"F V\u00e1zquez-Alonso","year":"2018","unstructured":"V\u00e1zquez-Alonso F, Puche-Sanz I, Cozar-Olmo JM. [Recommendations for follow-up in castration resistant prostate cancer.]. Arch Esp Urol. 2018;71:735\u201342.","journal-title":"Arch Esp Urol"},{"key":"1076_CR22","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","volume":"20","author":"H Beltran","year":"2014","unstructured":"Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014;20:2846\u201350.","journal-title":"Clin Cancer Res"},{"key":"1076_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108585","volume":"34","author":"RC Fernandes","year":"2021","unstructured":"Fernandes RC, Toubia J, Townley S, Hanson AR, Dredge BK, Pillman KA, et al. Post-transcriptional gene regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Rep. 2021;34:108585.","journal-title":"Cell Rep"},{"key":"1076_CR24","doi-asserted-by":"crossref","unstructured":"Seguier D, Parent P, Duterque-Coquillaud M, Labreuche J, Fromont-Hankard G, Dariane C, et al. Emergence of neuroendocrine tumors in patients treated with androgen receptor pathway inhibitors for metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2025;8:581\u201390.","DOI":"10.1016\/j.euo.2024.12.014"},{"key":"1076_CR25","doi-asserted-by":"publisher","first-page":"e2332900","DOI":"10.1001\/jamanetworkopen.2023.32900","volume":"6","author":"UG Falagario","year":"2023","unstructured":"Falagario UG, Abbadi A, Remmers S, Bjornebo L, Bogdanovic D, Martini A, et al. Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy. JAMA Netw Open. 2023;6:e2332900.","journal-title":"JAMA Netw Open"},{"key":"1076_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.brachy.2019.08.008","volume":"19","author":"AN Slade","year":"2020","unstructured":"Slade AN, Dahman B, Chang MG. Racial differences in the PSA bounce in predicting prostate cancer outcomes after brachytherapy: evidence from the Department of Veterans Affairs. Brachytherapy. 2020;19:6\u201312.","journal-title":"Brachytherapy"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01076-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01076-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01076-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:14Z","timestamp":1790719214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01076-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1076"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01076-w","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AM: Consulting or advisory role: Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, BMS, Bayer, Curium, Exact Sciences, Exelixis, Inc., Janssen, Lantheus Medical Imaging, Macrogenics, Merck, Novartis, Pfizer, Sanofi, Sumitomo Pharma, Telix Pharmaceuticals, Tolmar; Honoraria: Advanced Accelerator Applications, Astellas Scientific and Medical Affairs Inc., AstraZeneca, Bayer, Curium Pharma, Janssen, Janssen Oncology, Merck, Novartis, Pfizer, Telix Pharmaceuticals; Research funding: Astellas Scientific and Medical Affairs Inc., Bayer, Janssen, Pfizer, Seattle Genetics\/Astellas; Travel, accommodations, expenses: Bayer, Pfizer; Stock and other ownership: Vertex. CJDW: Consulting fees: Janssen Oncology, Nanostics Inc, Precision Point Specialty LLC, SESEN Bio; Honoraria\/travel: AbbVie, Astellas, Astra Zeneca, Bayer, EMD Serono, Haymarket Media, Healing and Cancer Foundation, Knight Therapeutics, Merck, Science & Medicine Canada, TerSera Canada, Tolmar Pharmaceuticals Canada; Research funding: Bayer, Knight Therapeutics, Tolmar Pharmaceuticals. SH: Employment: American Society for Clinical Oncology (ASCO); Honoraria: AVEO Oncology, Beigene, Bristol Myers Squibb, CG Oncology, Janssen, Sanofi. AJA: Consulting or advisory role: Astellas Scientific and Medical Affairs Inc, AstraZeneca, Bayer, Bristol-Myers Squibb, Epic Sciences, Exelixis, FORMA Therapeutics, GoodRx, IDEAYA Biosciences, Janssen, Merck, Myovant Sciences, Novartis, Pfizer; Research funding: Amgen (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), BeiGene (Inst), Bristol-Myers Squibb (Inst), Bristol-Myers Squibb (Inst), Constellation Pharmaceuticals (Inst), Dendreon (Inst), FORMA Therapeutics (Inst), Gilead Sciences (Inst), Janssen Oncology (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), Roche\/Genentech (Inst); Patents, royalties, other intellectual property: Circulating tumor cell novel capture technology (Inst); Travel, accommodations, expenses: Astellas Scientific and Medical Affairs Inc. PA: Employment: Bayer. MG: Employment: Bayer. FV: Employment: Bayer. MOG: Research funding: Bayer Vital, BMS, Intuitive Surgical; Consulting\/advisory role: Astellas, AstraZeneca, Bayer Vital, BMS, Eisai, EUSA Pharma, Gilead, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Roche Pharma AG, Takeda.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}